|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bristow R, Chang J, Ziogas A, et al: NCCN
treatment guidelines for ovarian cancer: A population-based
vali-dation study of structural and process quality measures.
Gynecologic Oncology. 130:e182013. View Article : Google Scholar
|
|
3
|
Seiya S and Hiroaki I: Ovarian cancer and
drug resistance. Current Obstetrics and Gynecology Reports.
4:18–25. 2015. View Article : Google Scholar
|
|
4
|
Lloyd KL, Cree IA and Savage RS:
Prediction of resistance to chemotherapy in ovarian cancer: A
systematic review. BMC Cancer. 15:1172015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Leamon PC, Lovejoy CD and Nguyen B:
Patient selection and targeted treatment in the management of
platinum-resistant ovarian cancer. Pharmgenomics Pers Med.
6:113–125. 2013.PubMed/NCBI
|
|
6
|
Go RS and Adjei AA: Review of the
comparative pharmacology and clinical activity of cisplatin and
carboplatin. J Clin Oncol. 17:409–422. 1999.PubMed/NCBI
|
|
7
|
Kelland L: The resurgence of
platinum-based cancer chemotherapy. Nat Rev Cancer. 7:573–584.
2007. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Claudia M, Jonathan AL and Pierluigi BP:
An overview of early investigational therapies for chemoresistant
ovarian cancer. Expert Opin Investig Drugs. 24:1163–1183. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Galluzzi L, Senovilla L, Vitale I, Michels
J, Martins I, Kepp O, Castedo M and Kroemer G: Molecular mechanisms
of cisplatin resistance. Oncogene. 31:1869–1883. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sorrentino A, Liu CG, Addario A, Peschle
C, Scambia G and Ferlini C: Role of microRNAs in drug-resistant
ovarian cancer cells. Gynecol Oncol. 111:478–486. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bayerlová M, Klemm F, Kramer F, Pukrop T,
Beißbarth T and Bleckmann A: Newly constructed network models of
different WNT signaling cascades applied to breast cancer
expression data. PLoS One. 10:e01440142015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Shin H, Kim JH, Lee YS and Lee YC: Change
in gene expression profiles of secreted frizzled-related proteins
(SFRPs) by sodium butyrate in gastric cancers: Induction of
promoter demethylation and histone modification causing inhibition
of Wnt signaling. Int J Oncol. 40:1533–1542. 2012.PubMed/NCBI
|
|
13
|
Xi Y and Chen Y: Wnt signaling pathway:
Implications for therapy in lung cancer and bone metastasis. Cancer
Lett. 353:8–16. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sidaway P: Prostate cancer: Wnt signaling
induces resistance. Nat Rev Urol. 12:5972015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Dellinger T, Warden C, Han E, et al: Wnt
pathway gene expression and association with clinicopathologic
characteristics in endometrial cancer-An analysis of The Cancer
Genome Atlas (TCGA). Gynecologic Oncology. 130:e892013. View Article : Google Scholar
|
|
16
|
Rosanò L, Cianfrocca R, Tocci P, Spinella
F, Di Castro V, Caprara V, Semprucci E, Ferrandina G, Natali PG and
Bagnato A: Endothelin A receptor/β-arrestin signaling to the Wnt
pathway renders ovarian cancer cells resistant to chemotherapy.
Cancer Res. 74:7453–7464. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Su HY, Lai HC, Lin YW, Liu CY, Chen CK,
Chou YC, Lin SP, Lin WC, Lee HY and Yu MH: Epigenetic silencing of
SFRP5 is related to malignant phenotype and chemoresistance of
ovarian cancer through Wnt signaling pathway. Int J Cancer.
127:555–567. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Laura R, Roberta C, Piera T, et al:
Endothelin A receptor/β-arrestin signaling to the Wnt pathway
renders ovarian cancer cells resistant to chemotherapy. Cancer
Research. 74:7463–7464. 2014.
|
|
19
|
Dawson K, Aflaki M and Nattel S: Role of
the Wnt-Frizzled system in cardiac pathophysiology: A rapidly
developing, poorly understood area with enormous potential. J
Physiol. 591:1409–1432. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chiurillo MA: Role of the Wnt/β-catenin
pathway in gastric cancer: An in-depth literature review. World J
Exp Med. 5:84–102. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhao H, Wei W, Sun Y, Gao J, Wang Q and
Zheng J: Interference with the expression of β-catenin reverses
cisplatin resistance in A2780/DDP cells and inhibits the
progression of ovarian cancer in mouse model. DNA Cell Biol.
34:55–62. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Barghout SH, Zepeda N, Xu Z, Steed H, Lee
CH and Fu Y: Elevated β-catenin activity contributes to carboplatin
resistance in A2780cp ovarian cancer cells. Biochem Biophys Res
Commun. 468:173–178. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Arend RC, Londoño-Joshi AI, Straughn JM Jr
and Buchsbaum DJ: The Wnt/β-catenin pathway in ovarian cancer: A
review. Gynecol Oncol. 131:772–779. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Matsumoto T, Yamazaki M, Takahashi H,
Kajita S, Suzuki E, Tsuruta T and Saegusa M: Distinct β-Catenin and
PIK3CA mutation profiles in endometriosis-associated ovarian
endometrioid and clear cell carcinomas. Am J Clin Pathol.
144:452–463. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
McConechy MK, Ding J, Senz J, Yang W,
Melnyk N, Tone AA, Prentice LM, Wiegand KC, McAlpine JN, Shah SP,
et al: Ovarian and endometrial endometrioid carcinomas have
distinct CTNNB1 and PTEN mutation profiles. Mod Pathol. 27:128–134.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Forda CE, Punnia-Moorthya G, Henrya CE,
Llamosas E, Nixdorf S, Olivier J, Caduff R, Ward RL and
Heinzelmann-Schwarz V: The non-canonical Wnt ligand, Wnt5a, is
upregulated and associated with epithelial to mesenchymal
transition in epithelial ovarian cancer. Gynecol Oncol.
134:338–345. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Niehrs C: The complex world of WNT
receptor signaling. Nat Rev Mol Cell Biol. 13:767–779. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Cizelsky W, Tata A, Kühl M and Kühl SJ:
The Wnt/JNK signaling target gene alcam is required for embryonic
kidney development. Development. 141:2064–2074. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Tong XG, Barbourb M, Houc K, Gao C, Cao S,
Zheng J, Zhao Y, Mu R and Jiang HR: Interleukin-33 predicts poor
prognosis and promotes ovarian cancer cell growth and metastasis
through regulating ERK and JNK signaling pathways. Mol Oncol.
10:113–125. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ye XL, Zhao YR, Weng GB, Chen YC, Wei XN,
Shao JP and Ji H: IL-33-induced JNK pathway activation confers
gastric cancer chemotherapy resistance. Oncol Rep. 33:2746–2752.
2015.PubMed/NCBI
|
|
31
|
De A: Wnt/Ca2+ signaling
pathway: A brief overview. Acta Biochim Biophys Sin (Shanghai).
43:745–756. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ali AY, Farrand L, Kim JY, Byun S, Suh JY,
Lee HJ and Tsang BK: Molecular determinants of ovarian cancer
chemoresistance: New insights into an old conundrum. Ann N Y Acad
Sci. 1271:58–67. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Poisson LM, Munkarah A, Madi H, Datta I,
Hensley-Alford S, Tebbe C, Buekers T, Giri S and Rattan R: A
metabolomic approach to identifying platinum resistance in ovarian
cancer. J Ovarian Res. 8:132015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Luna-Ulloa LB, Hernández-Maqueda JG,
Castañeda-Patlán MC and Robles-Flores M: Protein kinase C in Wnt
signaling: Implications in cancer initiation and progression. IUBMB
Life. 63:915–921. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Kagermeier-Schenk B, Wehner D, Özhan-Kizil
G, Yamamoto H, Li J, Kirchner K, Hoffmann C, Stern P, Kikuchi A,
Schambony A and Weidinger G: Waif1/5T4 inhibits Wnt/β-catenin
signaling and activates noncanonical Wnt pathways by modifying LRP6
subcellular localization. Dev Cell. 21:1129–1143. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
King TD, Zhang W, Suto MJ and Li Y:
Frizzled7 as an emerging target for cancer therapy. Cell Signal.
24:846–851. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Ishitani T, Kishida S, Hyodo-Miura J, Ueno
N, Yasuda J, Waterman M, Shibuya H, Moon RT, Ninomiya-Tsuji J and
Matsumoto K: The TAK1-NLK mitogen-activated protein kinase cascade
functions in the Wnt-5a/Ca(2+) pathway to antagonize
Wnt/beta-catenin signaling. Mol Cell Biol. 23:131–139. 2003.
View Article : Google Scholar : PubMed/NCBI
|
